In this episode, Dr. Kirk Barber speaks with Dr. David Croitoru about the long-standing concern linking IL-17 inhibitors with inflammatory bowel disease (IBD). Drawing on a comprehensive review of published cases and clinical trial data, Dr. Croitoru breaks down what the evidence actually shows—and how dermatologists should apply it in everyday practice.
They discuss:
- Reported rates of new-onset and exacerbated IBD with IL-17 inhibitors
- How these risks compare with baseline population risk
- Managing patients with family history, IBS-like symptoms, or IBD in long-term remission
- Why shared decision-making is essential when risks are low but consequences can be serious
- The role of real-world registry data in answering questions trials can’t
Dr. David Croitoru is a Toronto-based dermatologist and clinician-investigator at University Health Network and Women’s College Hospital. He leads Canada’s largest Pyoderma Gangrenosum clinic and supports national dermatology research and training through SKiN Canada.
Dr. Barber and his guests do not receive any financial reimbursement for the production of this podcast.
For more great CDA podcasts check out Dermalogues, our Residents podcast hosted by Dr Kerri Purdy.
To learn more about the work of the Canadian Dermatology Association, please visit our website at dermatology.ca
This podcast is produced by David McGuffin, and Clare and Graham McGuffin of ExploreProductions.ca
POWERED BY BLUBRRY
